Ambu A/S OMXCOP:AMBU_B:
OBTAINS FDA CLEARANCE FOR SINGLE-USE FLEXIBLE CYSTO-NEPHROSCOPY SOLUTION
Ambu Obtains FDA Clearance For Single-Use Flexible Cysto-Nephroscopy Solution
Watch Ambu's latest callAmbu (Copenhagen:AMBU B) Q3 2026 Earnings Call · Replay · Aug 26Read the transcript of Ambu (Copenhagen:AMBU B) Q3 2026 Earnings CallEarlier from Ambu
- Ambu A/S: Annual Trading Report 2024
- Ambu A/S: Quarterly Trading Report 2025 Q1
- AMBU_B: Strong Q2 growth and margin, guidance reaffirmed amid tariff and currency headwinds
- AMBU_B: Strong Q1 growth and margin expansion led to upgraded guidance and robust outlook
- AMBU_B: Raised guidance after strong Q1; endoscopy leads growth with new launches and operational gains
Later from Ambu
- Ambu rises as FDA issues import alerts on rival devices
- Ambu A/S: Quarterly Trading Report 2025 Q2
- Ambu A/S: Quarterly Trading Report 2024 Q4
- AMBU_B: Strong Q3 growth and raised guidance, despite FX and working capital headwinds
- AMBU_B: Ambitious strategy aims for global endoscopy leadership, 11%-13% CAGR, and 20%+ EBIT margin
Follow Ambu into a list and get an email when it puts out news.
Follow Ambu